Priscilla Kim1, Steven M Gordon2, Megan M Sheehan1, Michael B Rothberg3. 1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA. 2. Department of Infectious Disease, Cleveland Clinic, Cleveland, Ohio, USAand. 3. Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to be highly protective against reinfection and symptomatic disease. However, effectiveness against the Delta variant and duration of natural immunity remain unknown. METHODS: This retrospective cohort study included 325 157 patients tested for SARS-CoV-2 via polymerase chain reaction (PCR) from 9 March 2020 to 31 December 2020 (Delta variant analysis) and 152 656 patients tested from 9 March 2020 to 30 August 2020 (long-term effectiveness analysis) with subsequent testing through 9 September 2021. The primary outcome was reinfection, defined as a positive PCR test >90 days after the initial positive test. RESULTS: Among 325 157 patients tested before 31 December 2020, 50 327 (15.5%) tested positive. After 1 July 2021 (Delta dominant period), 40 (0.08%) initially positive and 1494 (0.5%) initially negative patients tested positive. Protection of prior infection against reinfection with Delta was 85.4% (95% confidence interval [CI], 80.0-89.3). For the long-term effectiveness analysis, among 152 656 patients tested before 30 August 2020, 11 186 (7.3%) tested positive. After at least 90 days, 81 (0.7%) initially positive and 7167 (5.1%) initially negative patients tested positive. Overall protection of previous infection was 85.7% (95% CI, 82.2-88.5) and lasted up to 13 months. Patients aged >65 years had slightly lower protection. CONCLUSIONS: SARS-CoV-2 infection is highly protective against reinfection with Delta. Immunity from prior infection lasts at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access.
BACKGROUND: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to be highly protective against reinfection and symptomatic disease. However, effectiveness against the Delta variant and duration of natural immunity remain unknown. METHODS: This retrospective cohort study included 325 157 patients tested for SARS-CoV-2 via polymerase chain reaction (PCR) from 9 March 2020 to 31 December 2020 (Delta variant analysis) and 152 656 patients tested from 9 March 2020 to 30 August 2020 (long-term effectiveness analysis) with subsequent testing through 9 September 2021. The primary outcome was reinfection, defined as a positive PCR test >90 days after the initial positive test. RESULTS: Among 325 157 patients tested before 31 December 2020, 50 327 (15.5%) tested positive. After 1 July 2021 (Delta dominant period), 40 (0.08%) initially positive and 1494 (0.5%) initially negative patients tested positive. Protection of prior infection against reinfection with Delta was 85.4% (95% confidence interval [CI], 80.0-89.3). For the long-term effectiveness analysis, among 152 656 patients tested before 30 August 2020, 11 186 (7.3%) tested positive. After at least 90 days, 81 (0.7%) initially positive and 7167 (5.1%) initially negative patients tested positive. Overall protection of previous infection was 85.7% (95% CI, 82.2-88.5) and lasted up to 13 months. Patients aged >65 years had slightly lower protection. CONCLUSIONS: SARS-CoV-2 infection is highly protective against reinfection with Delta. Immunity from prior infection lasts at least 13 months. Countries facing vaccine shortages should consider delaying vaccinations for previously infected patients to increase access.
Authors: Joanne Lacy; Anna Mensah; Ruth Simmons; Nick Andrews; M Ruby Siddiqui; Antoaneta Bukasa; Shennae O'Boyle; Helen Campbell; Kevin Brown Journal: Epidemiol Infect Date: 2022-05-24 Impact factor: 4.434
Authors: Alexander L Lundberg; Ramon Lorenzo-Redondo; Judd F Hultquist; Claudia A Hawkins; Egon A Ozer; Sarah B Welch; P V Vara Prasad; Chad J Achenbach; Janine I White; James F Oehmke; Robert L Murphy; Robert J Havey; Lori A Post Journal: JMIR Public Health Surveill Date: 2022-06-03
Authors: Stefan Pilz; Verena Theiler-Schwetz; Christian Trummer; Robert Krause; John P A Ioannidis Journal: Environ Res Date: 2022-02-08 Impact factor: 8.431
Authors: Hiam Chemaitelly; Houssein H Ayoub; Peter Coyle; Patrick Tang; Hadi M Yassine; Hebah A Al-Khatib; Maria K Smatti; Mohammad R Hasan; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al-Kuwari; Adeel A Butt; Hamad Eid Al-Romaihi; Mohamed H Al-Thani; Abdullatif Al-Khal; Roberto Bertollini; Laith J Abu-Raddad Journal: Nat Commun Date: 2022-08-09 Impact factor: 17.694
Authors: Tomás M León; Vajeera Dorabawila; Lauren Nelson; Emily Lutterloh; Ursula E Bauer; Bryon Backenson; Mary T Bassett; Hannah Henry; Brooke Bregman; Claire M Midgley; Jennifer F Myers; Ian D Plumb; Heather E Reese; Rui Zhao; Melissa Briggs-Hagen; Dina Hoefer; James P Watt; Benjamin J Silk; Seema Jain; Eli S Rosenberg Journal: MMWR Morb Mortal Wkly Rep Date: 2022-01-28 Impact factor: 35.301